ADA and DPP4

Data Source:
HPRD (in vitro)

		ADA	DPP4
Description		adenosine deaminase	dipeptidyl peptidase 4
Image
GO Annotations	Cellular Component	Extracellular Space Lysosome Cytosol Plasma Membrane External Side Of Plasma Membrane Cell Surface Membrane Cell Junction Dendrite Cytoplasm Neuronal Cell Body Cytoplasmic Vesicle Lumen	Extracellular Region Lysosomal Membrane Plasma Membrane Focal Adhesion Cell Surface Membrane Integral Component Of Membrane Apical Plasma Membrane Lamellipodium Endocytic Vesicle Lamellipodium Membrane Membrane Raft Intercellular Canaliculus Extracellular Exosome
	Molecular Function	Purine Nucleoside Binding Adenosine Deaminase Activity Protein Binding Zinc Ion Binding	Virus Receptor Activity Protease Binding Aminopeptidase Activity Serine-type Endopeptidase Activity Signaling Receptor Binding Protein Binding Serine-type Peptidase Activity Dipeptidyl-peptidase Activity Identical Protein Binding Protein Homodimerization Activity Chemorepellent Activity
	Biological Process	Response To Hypoxia Histamine Secretion Trophectodermal Cell Differentiation Liver Development Placenta Development Germinal Center B Cell Differentiation Positive Regulation Of Germinal Center Formation Negative Regulation Of Leukocyte Migration Negative Regulation Of Mature B Cell Apoptotic Process Adenosine Catabolic Process Deoxyadenosine Catabolic Process Cell Adhesion Aging Purine Ribonucleoside Monophosphate Biosynthetic Process Positive Regulation Of Heart Rate Positive Regulation Of B Cell Proliferation Purine Nucleotide Salvage Positive Regulation Of T Cell Differentiation In Thymus Response To Vitamin E Regulation Of Cell-cell Adhesion Mediated By Integrin T Cell Activation Negative Regulation Of Circadian Sleep/wake Cycle, Non-REM Sleep Response To Drug Response To Hydrogen Peroxide Purine-containing Compound Salvage Hypoxanthine Salvage Response To Morphine Positive Regulation Of Smooth Muscle Contraction DAMP Catabolic Process DATP Catabolic Process Inosine Biosynthetic Process Xanthine Biosynthetic Process Positive Regulation Of Alpha-beta T Cell Differentiation Lung Alveolus Development Peyer's Patch Development Embryonic Digestive Tract Development Negative Regulation Of Inflammatory Response Positive Regulation Of Calcium-mediated Signaling Positive Regulation Of T Cell Receptor Signaling Pathway Negative Regulation Of Adenosine Receptor Signaling Pathway Negative Regulation Of Penile Erection Negative Regulation Of Thymocyte Apoptotic Process Negative Regulation Of Mucus Secretion	Behavioral Fear Response Response To Hypoxia Proteolysis Cell Adhesion Positive Regulation Of Cell Population Proliferation Negative Regulation Of Extracellular Matrix Disassembly T Cell Costimulation Regulation Of Cell-cell Adhesion Mediated By Integrin Locomotory Exploration Behavior Psychomotor Behavior T Cell Activation Endothelial Cell Migration Viral Entry Into Host Cell Regulation Of Insulin Secretion Negative Chemotaxis Negative Regulation Of Neutrophil Chemotaxis
Pathways		Purine salvage	Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP)
Drugs		Pentostatin Dipyridamole FR221647 7,8-dihydroinosine FR117016 FR236913 6-hydroxy-1,6-dihydro purine nucleoside FR-234938 FR239087 FR230513 1-Deaza-Adenosine Nebularine (2S,3R)-3-(6-amino-9H-purin-9-yl)nonan-2-ol 1-((1R)-1-(HYDROXYMETHYL)-3-{6-[(3-PHENYLPROPANOYL)AMINO]-1H-INDOL-1-YL}PROPYL)-1H-IMIDAZOLE-4-CARBOXAMIDE 1-{(1R,2S)-2-HYDROXY-1-[2-(2-NAPHTHYLOXY)ETHYL]PROPYL}-1H-IMIDAZONE-4-CARBOXAMIDE 1-((1R,2S)-1-{2-[2-(4-CHLOROPHENYL)-1,3-BENZOXAZOL-7-YL]ETHYL}-2-HYDROXYPROPYL)-1H-IMIDAZOLE-4-CARBOXAMIDE	Atorvastatin Sitagliptin 2-Amino-3-Methyl-1-Pyrrolidin-1-Yl-Butan-1-One 5-(Aminomethyl)-6-(2,4-Dichlorophenyl)-2-(3,5-Dimethoxyphenyl)Pyrimidin-4-Amine (2s)-Pyrrolidin-2-Ylmethylamine 4-Iodo-L-phenylalanine Diisopropylphosphono Group 1-(1-phenylcyclopentyl)methylamine (S)-2-[(R)-3-amino-4-(2-fluorophenyl)butyryl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide Vildagliptin PSN9301 AMG-222 Bisegliptin Alogliptin Saxagliptin (1S)-2-[(2S,5R)-2-(AMINOMETHYL)-5-PROP-1-YN-1-YLPYRROLIDIN-1-YL]-1-CYCLOPENTYL-2-OXOETHANAMINE N-(TRANS-4-{(1S,2S)-2-AMINO-3-[(3S)-3-FLUOROPYRROLIDIN-1-YL]-1-METHYL-3-OXOPROPYL}CYCLOHEXYL)-N-METHYLACETAMIDE (2S,3S)-4-cyclopropyl-3-{(3R,5R)-3-[2-fluoro-4-(methylsulfonyl)phenyl]-1,2,4-oxadiazolidin-5-yl}-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-amine (2S,3S)-3-{3-[2-chloro-4-(methylsulfonyl)phenyl]-1,2,4-oxadiazol-5-yl}-1-cyclopentylidene-4-cyclopropyl-1-fluorobutan-2-amine (3R,4R)-4-(pyrrolidin-1-ylcarbonyl)-1-(quinoxalin-2-ylcarbonyl)pyrrolidin-3-amine (7R,8R)-8-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydroimidazo[1,2-a:4,5-c']dipyridin-7-amine (2S,3S)-3-{3-[4-(METHYLSULFONYL)PHENYL]-1,2,4-OXADIAZOL-5-YL}-1-OXO-1-PYRROLIDIN-1-YLBUTAN-2-AMINE (1S,2R,5S)-5-[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]-2-(2,4,5-TRIFLUOROPHENYL)CYCLOHEXANAMINE (2R)-4-[(8R)-8-METHYL-2-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[1,5-A]PYRAZIN-7(8H)-YL]-4-OXO-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE (2S,3S)-3-AMINO-4-(3,3-DIFLUOROPYRROLIDIN-1-YL)-N,N-DIMETHYL-4-OXO-2-(TRANS-4-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-6-YLCYCLOHEXYL)BUTANAMIDE (2S,3S)-3-AMINO-4-[(3S)-3-FLUOROPYRROLIDIN-1-YL]-N,N-DIMETHYL-4-OXO-2-(TRANS-4-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-5-YLCYCLOHEXYL)BUTANAMIDE (3R)-4-[(3R)-3-AMINO-4-(2,4,5-TRIFLUOROPHENYL)BUTANOYL]-3-METHYL-1,4-DIAZEPAN-2-ONE 4'-[(1R)-1-amino-2-(2,5-difluorophenyl)ethyl]biphenyl-3-carboxamide (2R,3R)-7-(methylsulfonyl)-3-(2,4,5-trifluorophenyl)-1,2,3,4-tetrahydropyrido[1,2-a]benzimidazol-2-amine 7-(aminomethyl)-6-(2-chlorophenyl)-1-methyl-1H-benzimidazole-5-carbonitrile 4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one METHYL 4-{[({[(2R,5S)-5-{[(2S)-2-(AMINOMETHYL)PYRROLIDIN-1-YL]CARBONYL}PYRROLIDIN-2-YL]METHYL}AMINO)CARBONYL]AMINO}BENZOATE (1S)-2-[(2S,5R)-2-(AMINOMETHYL)-5-ETHYNYLPYRROLIDIN-1-YL]-1-CYCLOPENTYL-2-OXOETHANAMINE 1-biphenyl-2-ylmethanamine (1S,3S,5S)-2-{(2S)-2-amino-2-[(1R,3S,5R,7S)-3-hydroxytricyclo[3.3.1.1~3,7~]dec-1-yl]acetyl}-2-azabicyclo[3.1.0]hexane-3-carbonitrile (2R)-N-[(2R)-2-(DIHYDROXYBORYL)-1-L-PROLYLPYRROLIDIN-2-YL]-N-[(5R)-5-(DIHYDROXYBORYL)-1-L-PROLYLPYRROLIDIN-2-YL]-L-PROLINAMIDE (3R,4S)-1-{6-[3-(METHYLSULFONYL)PHENYL]PYRIMIDIN-4-YL}-4-(2,4,5-TRIFLUOROPHENYL)PYRROLIDIN-3-AMINE N-({(2S)-1-[(3R)-3-AMINO-4-(2-FLUOROPHENYL)BUTANOYL]PYRROLIDIN-2-YL}METHYL)BENZAMIDE (4R,5R)-5-AMINO-1-[2-(1,3-BENZODIOXOL-5-YL)ETHYL]-4-(2,4,5-TRIFLUOROPHENYL)PIPERIDIN-2-ONE (3R,4S)-1-(3,4-DIMETHOXYPHENYL)-3-(3-METHYLPHENYL)PIPERIDIN-4-AMINE 1-[2-(S)-AMINO-3-BIPHENYL-4-YL-PROPIONYL]-PYRROLIDINE-2-(S)-CARBONITRILE ABT-341 (2R)-4-(2-BENZOYL-1,2-DIAZEPAN-1-YL)-4-OXO-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE (3R,4R)-1-{6-[3-(METHYLSULFONYL)PHENYL]PYRIMIDIN-4-YL}-4-(2,4,5-TRIFLUOROPHENYL)PIPERIDIN-3-AMINE Gosogliptin N-({(2S)-1-[(3R)-3-amino-4-(3-chlorophenyl)butanoyl]pyrrolidin-2-yl}methyl)-3-(methylsulfonyl)benzamide (3R,4S)-1-[6-(6-METHOXYPYRIDIN-3-YL)PYRIMIDIN-4-YL]-4-(2,4,5-TRIFLUOROPHENYL)PYRROLIDIN-3-AMINE 6-(4-{(1S,2S)-2-AMINO-1-[(DIMETHYLAMINO)CARBONYL]-3-[(3S)-3-FLUOROPYRROLIDIN-1-YL]-3-OXOPROPYL}PHENYL)-1H-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-4-IUM 7-BENZYL-1,3-DIMETHYL-8-PIPERAZIN-1-YL-3,7-DIHYDRO-PURINE-2,6-DIONE 2-({2-[(3R)-3-AMINOPIPERIDIN-1-YL]-4-OXOQUINAZOLIN-3(4H)-YL}METHYL)BENZONITRILE 4-[(3R)-3-{[2-(4-FLUOROPHENYL)-2-OXOETHYL]AMINO}BUTYL]BENZAMIDE 2-({8-[(3R)-3-AMINOPIPERIDIN-1-YL]-1,3-DIMETHYL-2,6-DIOXO-1,2,3,6-TETRAHYDRO-7H-PURIN-7-YL}METHYL)BENZONITRILE Linagliptin Dutogliptin
Diseases		T-B-Severe combined immunodeficiencies (SCIDs), including the following four diseases: Adenosine deaminase (ADA) deficiency; Recombinase activating gene (RAG) deficiencies; Artemis deficiency; Reticular dysgenesis
GWAS		Inflammatory bowel disease ( 28067908) Ulcerative colitis ( 28067908 23128233)	Asthma ( 32296059) Blood osmolality (transformed sodium) ( 28360221) Brain morphology (min-P) ( 32665545) Brain morphology (MOSTest) ( 32665545) Cognitive ability ( 29186694) Cognitive ability (MTAG) ( 29186694) Cortical surface area (MOSTest) ( 32665545) Cortical thickness (MOSTest) ( 32665545) Dentate gyrus molecular layer volume ( 30279459) General cognitive ability ( 29844566) Hippocampal tail volume ( 30279459) Hippocampal tail volume (corrected for total hippocampal volume) ( 30279459) Hippocampal volume ( 22504421) Intelligence (MTAG) ( 29326435) Multiple sclerosis ( 31604244) Reaction time ( 29844566) Regular attendance at a pub or social club ( 29970889) Rheumatoid arthritis ( 24782177) Schizophrenia ( 25056061 29483656) Smoking initiation (ever regular vs never regular) ( 30679032) Smoking status (ever vs never smokers) ( 30643258) Subcortical volume (min-P) ( 32665545) Subcortical volume (MOSTest) ( 32665545) Subiculum volume ( 30279459) Total hippocampal volume ( 30279459) Tourette syndrome ( 30818990)
Interacting Genes		11 interacting genes: ADORA1 ADORA2A ADORA2B DPP4 DRD1 GRB2 NR3C1 PIAS2 SGCD TERF2IP TINF2	16 interacting genes: ADA CCL11 CCL22 CCL3L1 CCL5 CD4 CPAMD8 CXCL10 CXCL11 CXCL12 CXCL9 CXCR4 DKK1 FAP GRP PTPRC
Entrez ID		100	1803
HPRD ID		00038	02187
Ensembl ID		ENSG00000196839	ENSG00000197635
Uniprot IDs		A0A0S2Z381 F5GWI4 P00813	P27487
PDB IDs		1M7M 3IAR	1J2E 1N1M 1NU6 1NU8 1PFQ 1R9M 1R9N 1RWQ 1TK3 1TKR 1U8E 1W1I 1WCY 1X70 2AJL 2BGN 2BGR 2BUB 2FJP 2G5P 2G5T 2G63 2HHA 2I03 2I78 2IIT 2IIV 2JID 2OAG 2OGZ 2OLE 2ONC 2OPH 2OQI 2OQV 2P8S 2QJR 2QKY 2QOE 2QT9 2QTB 2RGU 2RIP 3BJM 3C43 3C45 3CCB 3CCC 3D4L 3EIO 3F8S 3G0B 3G0C 3G0D 3G0G 3H0C 3HAB 3HAC 3KWF 3KWJ 3NOX 3O95 3O9V 3OC0 3OPM 3Q0T 3Q8W 3QBJ 3SWW 3SX4 3VJK 3VJL 3VJM 3W2T 3WQH 4A5S 4DSA 4DSZ 4DTC 4G1F 4J3J 4JH0 4KR0 4L72 4LKO 4N8D 4N8E 4PNZ 4PV7 4QZV 5I7U 5ISM 5J3J 5KBY 5T4B 5T4E 5T4F 5T4H 5Y7H 5Y7J 5Y7K 5ZID 6B1E 6B1O
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?